The mutation causes Kv7.2 membrane channels to stop working, like brakes stuck in the closed position. Potassium molecules (K+) can’t flow through the channel.
With potassium current blocked, children may experience frequent seizures and profound developmental delays
Knopp’s Kv7 platform has discovered modulators that release the brakes and restore potassium current in brain cells.
Experimental medicine studies and laboratory evidence suggests that restoring the function of the Kv7.2 protein reduces deficiencies caused by KCNQ2 mutations, creating hope that Kv7 modulators may help control seizures and improve or normalize brain development.
Knopp’s pipeline consists of investigational drug products that have not been approved by the U.S. Food and Drug Administration. These investigational drug products are undergoing clinical study to verify their safety and effectiveness.